BioXcel Therapeutics, Inc. Inventory Write-down
BioXcel Therapeutics, Inc. (BTAI) reported Inventory Write-down of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-13
- BioXcel Therapeutics, Inc. inventory write-down for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. inventory write-down for the quarter ending 2026-03-31 was $265.00K.
- BioXcel Therapeutics, Inc. inventory write-down for the quarter ending 2025-12-31 was $13.00K, a 98.33% decline year-over-year.
- BioXcel Therapeutics, Inc. inventory write-down for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. inventory write-down for fiscal 2025 was $108.00K, a 94.55% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. inventory write-down for fiscal 2024 was $1.98M, a 66.25% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. inventory write-down for fiscal 2023 was $1.19M.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | $265.00K 10-Q · filed 2026-08-13 | $278.00K derived: sum of 3 quarters · filed 2026-08-13 | $278.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $265.00K 10-Q · filed 2026-05-15 | $278.00K derived: sum of 2 quarters · filed 2026-05-15 | $278.00K derived: sum of 3 quarters · filed 2026-05-15 | $373.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $13.00K derived: sum of 2 quarters · filed 2026-03-27 | $108.00K derived: sum of 3 quarters · filed 2026-08-13 | $108.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $95.00K derived: sum of 2 quarters · filed 2026-08-13 | $95.00K 10-Q · filed 2025-11-12 | $873.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $95.00K 10-Q · filed 2026-08-13 | $95.00K 10-Q · filed 2026-08-13 | $873.00K derived: sum of 3 quarters · filed 2026-08-13 | $2.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | $778.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.94M derived: sum of 3 quarters · filed 2026-05-15 | $1.94M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $778.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.94M derived: sum of 2 quarters · filed 2026-03-27 | $1.94M derived: sum of 3 quarters · filed 2026-03-27 | $1.98M 10-K · filed 2026-03-27 |
| 2024-09-30 | $1.16M 10-Q · filed 2025-11-12 | $1.16M derived: sum of 2 quarters · filed 2025-11-12 | $1.20M 10-Q · filed 2025-11-12 | $1.90M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $45.00K 10-Q · filed 2025-08-12 | $741.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.24M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $45.00K 10-Q · filed 2025-05-12 | $741.00K derived: sum of 2 quarters · filed 2025-05-12 | $1.24M derived: sum of 3 quarters · filed 2025-05-12 | $1.24M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $696.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.19M derived: sum of 2 quarters · filed 2025-03-28 | $1.19M derived: sum of 3 quarters · filed 2025-03-28 | $1.19M 10-K · filed 2025-03-28 |
| 2023-09-30 | $495.00K 10-Q · filed 2024-11-14 | $495.00K derived: sum of 2 quarters · filed 2024-11-14 | $495.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |